What is Global Antibody-drug Conjugates Market?
The Global Antibody-drug Conjugates Market is a rapidly evolving sector in the pharmaceutical industry. Antibody-drug conjugates (ADCs) are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. They are complex molecules composed of an antibody linked to a biologically active cytotoxic (anti-cancer) payload or drug. ADCs combine the unique targeting capabilities of antibodies with the cancer-killing ability of cytotoxic drugs, allowing sensitive discrimination between healthy and diseased tissue. This means that ADCs have the potential to spare healthy cells and reduce the side effects of chemotherapy while maximizing its effectiveness against cancer cells.
Adcetris, Kadcyla in the Global Antibody-drug Conjugates Market:
Adcetris and Kadcyla are two prominent drugs in the Global Antibody-drug Conjugates Market. Adcetris (brentuximab vedotin) is an ADC used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It works by binding to a protein called CD30, which is present on the surface of some cancer cells, and then releasing a toxic substance into those cells. Kadcyla (ado-trastuzumab emtansine), on the other hand, is used to treat HER2-positive metastatic breast cancer. It combines the HER2-targeting properties of trastuzumab (Herceptin) with the cytotoxic activity of a drug called DM1. Both these drugs represent the innovative approach of the ADCs, targeting only the cancer cells and sparing the healthy ones, thus reducing the side effects and improving the patient's quality of life.
Breast Cancer, Lymphoma in the Global Antibody-drug Conjugates Market:
The Global Antibody-drug Conjugates Market has shown significant potential in the treatment of various types of cancers, including breast cancer and lymphoma. In breast cancer, ADCs like Kadcyla have shown promising results in treating HER2-positive metastatic breast cancer, a type of cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. In the case of lymphoma, drugs like Adcetris have been effective in treating Hodgkin lymphoma and systemic anaplastic large cell lymphoma. The targeted approach of these drugs, which allows them to deliver cytotoxic agents directly to cancer cells while sparing healthy cells, has the potential to revolutionize cancer treatment and improve patient outcomes.
Global Antibody-drug Conjugates Market Outlook:
The Global Antibody-drug Conjugates Market is experiencing a steady growth. In 2022, the market was valued at US$ 2831.3 million and it is projected to reach US$ 3919.8 million by 2029. This growth is expected to occur at a Compound Annual Growth Rate (CAGR) of 4.7% during the forecast period of 2023-2029. The market is geographically segmented with North America holding the largest market share of about 59%. Europe follows closely, accounting for about 27% of the market share. Takeda, a Japanese multinational pharmaceutical and biopharmaceutical company, is the largest manufacturer in this market, holding about 57% of the revenue market share.
| Report Metric | Details |
| Report Name | Antibody-drug Conjugates Market |
| Accounted market size in 2023 | US$ 2975.7 million |
| Forecasted market size in 2029 | US$ 3919.8 million |
| CAGR | 4.7 |
| Base Year | 2023 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| Segment by Region |
|
| By Company | ImmunoGen, Seattle Genetics, Roche, Takeda |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
